{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-038756","form_type":"8-K","ticker":"TARA","cik":"0001359931","company_name":"Protara Therapeutics, Inc.","filed_at":"2024-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.082229+00:00","generated_at":"2026-06-03T00:11:50.080934+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.72,"calibrated_materiality_score":0.72,"confidence":"high","headline":"Protara Therapeutics Q1 net loss $11.1M; cash runway into 2026 after $42M private placement","bullets":["Q1 net loss $11.1M ($0.97/sh) vs $9.0M ($0.80/sh) YoY; R&D spend rose to $7.7M from $5.1M.","Cash, equivalents and marketable securities $55.2M at Mar 31, 2024; combined with $42M net from April PIPE funds operations into 2026.","TARA-002 in NMIBC: 3-month CR rate 38% overall; 63% in CIS-only; no Grade 3+ related AEs.","ADVANCED-2 interim data (BCG-unresponsive/naïve) expected 2H 2024; registrational path aligned with FDA guidance.","FDA aligned on registrational path for IV Choline Chloride as choline source for PN-dependent patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-038756","json":"https://secwatch.observer/filing/0001213900-24-038756.json","markdown":"https://secwatch.observer/filing/0001213900-24-038756.md","text":"https://secwatch.observer/filing/0001213900-24-038756.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1359931/000121390024038756/0001213900-24-038756-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1359931/000121390024038756/ea0204875-8k_protara.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T00:11:50.080934+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"10e20cbe24a3fb7a259477e3e2249a5d1646a947","claim":"Protara Therapeutics, Inc. reported financial results for first quarter ended March 31, 2024.","evidence_excerpt":"On May 2, 2024, Protara Therapeutics, Inc. (the \"Company\") announced its financial results for the quarter ended March 31, 2024 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1359931/000121390024038756/0001213900-24-038756-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}